MONTREAL and PARSIPPANY, NJ -- (MARKET WIRE) -- September 18, 2006 -- TOPIGEN Pharmaceuticals Inc., an emerging biopharmaceutical company specializing in developing treatments for respiratory diseases, today announced that it has selected its next clinical candidate for Chronic Obstructive Pulmonary Disease (COPD). The compound, TPI-1100, is a novel, potent RNA-targeting inhibitor of multiple phosphodiesterases (PDEs), a group of enzymes that are validated targets of COPD. The compound will begin full scale development and undergo formal scale-up, manufacturing and toxicology studies to support clinical development activities, which are scheduled to begin in 2007.
